Carras, S., Torroja, A., Emadali, A., Montaut, E., Daguindau, N., Tempescul, A., Moreau, A., Tchernonog, E., Schmitt, A., Houot, R., Dartigeas, C., Barbieux, S., Corm, S., Banos, A., Fouillet, L., Dupuis, J., Macro, M., Fleury, J., Jardin, F., Sarkozy, C., Damaj, G., Feugier, P., Fornecker, L. M., Chabrot, C., Dorvaux, V., Bouabdallah, K., Amorim, S., Garidi, R., Voillat, L., Joly, B., Morineau, N., Moles, M. P., Zerazhi, H., Fontan, J., Arkam, Y., Alexis, M., Delwail, V., Vilque, J. P., Ysebaert, L., Burroni, B., Callanan, M., Le Gouill, S. and Gressin, R. (2020) “Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i&gt; mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2023.283724.